EMA to consider rolling review for Merck’s molnupiravir in coming

BRUSSELS (Reuters) – The European Medicines Agency will consider in the coming days whether to launch a rolling review of Merck’s experimental COVID-19 pill, its head of vaccine strategy said on Tuesday

An experimental antiviral pill developed by Merck & Co could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, interim data showed last week.

“We will be considering whether to start a rolling review for this compound in the next days. And of course, the idea is to understand if the data supports such (a) rolling review,” Marco Cavaleri, the EMA’s head of vaccine strategy, told reporters, when asked about Merck’s drug.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.